NCT02910700 2025-12-17
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT06194929 2025-12-03
DETERMINE
University of Utah
Phase 1/2 Recruiting
NCT06887088 2025-10-01
ENCEFALO
Grupo Español Multidisciplinar de Melanoma
Phase 2 Recruiting
NCT03898908 2025-05-21
EBRAIN-MEL
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT03973918 2024-10-31
BRAF
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT04800822 2024-10-22
PF-07284892 in Participants With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT04074096 2024-06-03
BEPCOME-MB
UNICANCER
Phase 2 Active not recruiting
NCT03563729 2023-07-13
MEMBRAINS
Herlev Hospital
Phase 2 Recruiting
NCT03911869 2023-05-31
POLARIS
Pfizer
Phase 2 Terminated